SELUMETINIB, SELUMETINIB, Placebo to match Selumetinib capsules, 10 and 25 mg.
KOMET D134BC00001
Phase 3 small_molecule active
Quick answer
SELUMETINIB, SELUMETINIB, Placebo to match Selumetinib capsules, 10 and 25 mg. for Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN). is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active